The Dynasty model combines the work of a biotech company with that of a life sciences investor.
The biotech company partners with UK innovators who have developed products that are both relevant to China and already sufficiently developed to be commercialised in China. Dynasty develops the products and shares the downstream value with the innovators. Meanwhile the investment business sources Chinese capital to fund the UK biotech activities, and provides growth capital to larger science businesses in order to develop products in China.
The Dynasty model is a novel alternative to venture capital, powered by foreign direct investment, generating new exports for UK biotechs.
To view English version: click here
To view Chinese version: 点击这里为影片中文字幕
I CAN run a marathon!
Today I proved something extraordinary to myself: even I - non-running, unfit, couch potato well into his late 50s - am capable of runnin...Read More
George Freeman MP supports new China:UK link
This week saw the launch of the Window-on-Wuhan Program in Cambridge UK, led by British entrepreneurs Dr Simon Haworth, Richard Leaver and t...Read More
A ‘sure thing’ funding pitch in China
I am back in Wuhan, Hubei Province, pitching for grant money. Wuhan Biolake, two hours flight time west of Shanghai, runs an annual fundi...Read More
The tale of 6 generations linked to China
6 generations: Henry Theodore, Harry, Lady Dorothy, Anthony, Simon, and George “For my children and me, China is the future” --- A s...Read More
Come. To. China.
Sometimes China can seem like a long way away. But for some it is home, life, work environment, normal. The oppo...
"The UK Government recognises the strong potential for collaboration between the UK and China and actively welcomes partnership for innovation.”–UK Government support, Office for Life Sciences 2013
“The UK Life Sciences Strategy recognises that we must use our outstanding science base to its fullest potential in order that we remain at the forefront of the new life sciences landscape. Dynasty itself provides access for international partners to some of the best life science technology in the world.”–UK Government support, Office for Life Sciences 2013
“Dynasty Biotechnology provides further evidence of the UK's position as the global hub for life sciences, attracting global pharma companies to the UK as their European location of choice, and demonstrating the value of UK life sciences innovation in China - one of the world's most important markets. "–UK Government support, Office for Life Sciences 2013
"Dynasty Biotechnology enters the market at a time when all recognise the value of our Sino-UK relationship."–UK Government support, Office for Life Sciences 2013